Key result
Ferumoxytol CMR offers a safe, gadolinium-free alternative for high-resolution imaging in congenital heart disease.
Why the study?
Standard gadolinium-enhanced MRI faces limitations including precise bolus timing, long scan duration, complex protocols, and small structure imaging in congenital heart disease, which ferumoxytol may mitigate.
What is the utility and safety of ferumoxytol-enhanced cardiovascular magnetic resonance imaging and angiography in pediatric and adult patients with congenital heart disease?
What is the utility and safety of ferumoxytol-enhanced cardiovascular magnetic resonance imaging and angiography in pediatric and adult patients with congenital heart disease?
Ferumoxytol serves as a valuable alternative contrast agent for cardiovascular magnetic resonance imaging in congenital heart disease, overcoming limitations of standard gadolinium.
May support ferumoxytol-enhanced CMR as gadolinium-free option in congenital heart disease; extends review evidence but leaves open prospective validation.
Cardiac magnetic resonance imaging and angiography have a crucial role in the diagnostic evaluation and follow up of pediatric and adult patients with congenital heart disease. Although much of the information required of advanced imaging studies can be provided by standard gadolinium-enhanced magnetic resonance imaging, the limitations of precise bolus timing, long scan duration, complex imaging protocols, and the need to image small structures limit more widespread use of this modality. Recent experience with off-label diagnostic use of ferumoxytol has helped to mitigate some of these barriers. Approved by the U.S. FDA for intravenous treatment of anemia, ferumoxytol is an ultrasmall superparamagnetic iron oxide nanoparticle that has a long blood pool residence time and high relaxivity. Once metabolized by macrophages, the iron core is incorporated into the reticuloendothelial system. In this work, we aim to summarize the evolution of ferumoxytol-enhanced cardiovascular magnetic resonance imaging and angiography and highlight its many applications for congenital heart disease.
No takes yet. Share an insight, caveat, or question.
Renella et al. (2022) conducted a review in Congenital heart disease. Ferumoxytol-enhanced CMR/MRA vs. Gadolinium-based contrast agents (GBCAs) was evaluated. Ferumoxytol-enhanced cardiovascular magnetic resonance imaging provides a safe, gadolinium-free alternative that facilitates high-resolution, steady-state evaluation of complex pediatric and adult congenital heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: